In Brief: U.K. may consolidate AER system, New York restricts DXM sales, Actavis divests oral contraceptives, homeopathic earache products warned
This article was originally published in The Tan Sheet
Executive Summary
U.K. eyes consolidating AER system; NY restricts DXM sales; Actavis divests oral contraceptives; ScriptPro simplifies NPLEx; firms warned for homeopathic earache products; tainted supplement recalls; CRN seeks more time for medical food comments; and vitamin K2 gains in popularity.
You may also be interested in...
In Brief: Clearblue estimates weeks, Barry Meltzer dies, P&G eliminating phthalates and triclosan, NPLEx adds Delaware
P&G Clearblue pregnancy test estimates week of conception; AHPA co-founder Meltzer dies; P&G to eliminate phthalates, triclosan; CSPI, Aloe Science Council square off; Delaware joins NPLEx; IADSA focuses on supplement safety guidelines; Pharmavite expands Alabama facility.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.